Trinity Biotech plc (TRIB)

Market Cap	13.98M
Revenue (ttm)	56.83M
Net Income (ttm)	-24.02M
Shares Out	7.64M
EPS (ttm)	-4.96
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	11,194
Open	1.832
Previous Close	1.850
Day's Range	1.830 - 1.913
52-Week Range	1.790 - 5.500
Beta	1.23
Analysts	n/a
Price Target	n/a
Earnings Date	Apr 4, 2024

About TRIB

Trinity Biotech plc acquires, together with its subsidiaries, develops, manufactures, and markets medical diagnostic products for the clinical laboratory and point-of-care (POC) segments of the diagnostic market in the Americas, Africa, Asia, and Europe. The company offers clinical laboratory products, including diagnostic tests and instrumentation, which detect infectious diseases, such as lyme disease; sexually transmitted diseases consisting syphilis and herpes; SARS-CoV-2; and epstein barr, measles, mumps, toxoplasmosis, cytomegalovirus, ru...

• Industry: Diagnostics & Research
• Sector: Healthcare
• Founded: 1992
• Employees: 398
• Stock Exchange: NASDAQ
• Ticker Symbol: TRIB

Financial Performance

In 2023, TRIB's revenue was $56.83 million, a decrease of -9.10% compared to the previous year's $62.52 million. Losses were -$24.02 million, -41.43% less than in 2022.